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THE CHALLENGE OF HIV IN TB CONTROL
The HIV epidemic in South Africa has been associated with a 
similar increase in TB case load as reported in other sub-
Saharan countries. The incidence of TB has increased markedly
among HIV-infected individuals, with a proportional increase
in smear-negative pulmonary disease, extrapulmonary
involvement, frequent atypical clinical presentations, an
increased mortality and a strong association with multidrug
and extreme drug-resistant TB. The impact of HIV on a TB clinic
is illustrated by the changes in TB notification data from a
Cape Town peri-urban township over the last 10 years as HIV
adult seroprevalence has increased from 8% in 1996 to 23%
in 2005.6 During this period TB incidence rates have increased
4.75-fold from 400/100 000 in 1996 to 190 000/100 000 in
2005, with the highest increase occurring in 20 - 40-year-
olds.6 In 2005 the overall TB notification rate was 5.4-fold
higher among HIV-positive individuals (5 140/100 000) than
HIV-negative individuals (953/100 000) (Table I). Smear-
negative disease notification was 8-fold higher among HIV-
positive individuals (1 891/100 000) than HIV-negative
individuals (238/100 000). Despite a plateauing of HIV
seroprevalence, TB notifications have continued to increase.6
THE CHALLENGE OF TB IN AN ART PROGRAMME
The diagnosis of TB is particularly challenging in 
patients accessing antiretroviral therapy (ART) when their HIV
infection is advanced. The Hannan Crusaid clinic was the first
dedicated public sector ART facility in South Africa and
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It is estimated that 2 billion of the world's population are latently infected with Mycobacterium tuberculosis (Mtb) with a
resultant 8 - 9 million cases of active tuberculosis (TB) and 1.6 million deaths annually.1 The tools used for diagnosis of TB have
remained largely unchanged since the 1880s when sputum microscopy, Mtb culture on solid media, tuberculin skin testing and
chest radiology were initially developed. In 1991 the World Health Assembly set targets to be reached in 2005 for 70% case
finding of smear-positive TB, which represents 6 million cases to be identified per annum.2 A second target was that 80%
(5 million) of those identified cases should complete anti-TB treatment.2 Subsequently the millennium development goals of
2000 set a target of halving the prevalence of TB disease from 300/100 000 to 150/100 000 and deaths from 30/100 000 to
15/100 000 by 2015.3 While progress toward these targets was being made in countries with established market economies
there was a quadrupling of TB incidence between 1990 and 2005 in most African countries. In 2005 the World Health
Organization Regional Committee for Africa declared TB an emergency for the African region.4
In South Africa in 2005 the WHO estimated that of 284 592 TB cases 270 360 were notified to the national TB control
programme, representing a somewhat ambitious reported case finding proportion of 95%.5 The proportion treated under the
directly observed treatment (DOTS) programme is 94%, and HIV prevalence among notified cases was 58% (97.5% confidence
interval (CI) 49 - 65%). South Africa is a middle-income country and is relatively well provided with 143 laboratories
performing sputum smears, and 18 culture laboratories also capable of performing drug sensitivity testing.5 Multidrug
resistance (MDR) in new TB cases varies between provinces from 0.9% to 3.6%, while MDR is higher among retreatment cases,
with prevalence rates varying between 1.8% to 13.7% in different provincial surveys.
TB Total adult HIV-positive HIV-negative HIV+ve/HIV
type population adults adults -ve ratio
(PTB) 1 931 5 140 953 5.4
Smear-positive 
PTB 1 307 3 248 715 4.5
Smear-negative 
PTB 624 1 891 238 7.9
PTB = pulmonary tuberculosis.
TABLE I. ADULT PULMONARY TB NOTIFICATION RATES PER
100 000 IN A CAPE TOWN PERI-URBAN  TOWNSHIP 2005
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currently provides treatment to 3 000 patients. Eighty-nine
per cent of those accessing ART have symptomatic HIV disease
(WHO clinical stage 3 and 4) with a median CD4 cell count of
95 cells/µl. More than 50% have a history of prior completed
TB treatment, 15% are on current TB treatment, 11% are
diagnosed with previously undiagnosed TB, and a further 10%
develop new incident TB after initiation of ART.7 Multivariate
analysis identified risk factors for development of incident TB
to be WHO stage 3 and 4 disease (relative risk (RR) 5.9, 95%
CI 3.2 - 10.9 and 8.9 95% CI 4.6 - 17.3 respectively), baseline
CD4 cell count (RR 1.41, 95% CI 1.2 - 3.1 for each 50 CD4 cell
count decline) and baseline viral load (RR 1.4, 95% CI 1.1 -
1.8). A  history of completed TB treatment within the previous
2 years was associated with significant protection against
incident TB (RR 0.21, 95% CI 0.2 - 0.7).
THE CHALLENGE OF HIV/TB IN A COMMUNITY
The high case finding proportion (close to 100%)2 reported for
the South African TB control programme is based on an
estimate of the TB burden. The programme is based on passive
case finding together with directly observed therapy of those
cases identified. Active case finding enables a direct
assessment of TB burden and can identify differing case
finding proportions for either HIV-negative or HIV-positive
individuals. Active TB case finding and HIV testing of a
randomly selected sample of 762 individuals living in
Masiphumelele, a peri-urban township outside Cape Town,
was performed in 2005 and identified 23% of adults to be
seropositive for HIV, 11 individuals with prevalent treated TB
and a further 12 individuals with previously unrecognised
smear-positive (N = 6) and culture-positive (N = 6) pulmonary
TB.8 Both HIV infection and a history of recent incarceration
were strongly associated with TB. The TB prevalence among
HIV-infected individuals was 7.6%, of which 4.4% was smear-
positive disease. The case finding proportion for HIV-negative
individuals (ratio of prevalence of treated to prevalence of
treated and untreated with smear-positive disease) was 67%
(95% CI 41 - 100), while that for HIV-positive individuals with
smear-positive disease was 37% (95% CI 25 - 53) (Table II). In
this community, with a single TB clinic providing care to the
whole community, the TB control programme appeared to
perform less well for those with HIV infection than for those
who were HIV negative. 
THE CHALLENGE OF MULTI- AND EXTREMELY 
DRUG-RESISTANT TB
In 2005 an outbreak of extremely drug-resistant TB (XDR)
was recognised in Tugela Ferry, situated in a rural area of
northern KwaZulu-Natal. A report of the first 53 cases was
published in 2006.9 The epidemic was recognised in
predominantly HIV-positive individuals and was characterised
by an extremely high early mortality rate. Over 50% of cases of
XDR died within 30 days of presentation. Eighty per cent of the
identified cases had positive sputum smears and 25% had
evidence of extrapulmonary involvement. Analysis of risk
factors for XDR identified that 55% had no history of prior
treatment for TB, indicating that these cases had primary
rather than acquired resistance. Only 15% had a history of
treatment default or failure. The one factor which was of
concern was that 67% gave a history of admission to the local
health facility, raising the concern that nosocomial
transmission may have played a significant role in the
epidemic. XDR cases have continued to be recognised, and 266
cases have been confirmed of which 264 were HIV-positive.
This epidemic illustrates the potential problems associated
with integration of HIV and TB programmes and the increasing
need for rapid diagnosis of initial TB infection in both HIV-
positive and negative individuals and recognition of early
treatment failure and development of resistance within a
treatment programme.
CURRENT TB DIAGNOSTICS
Current TB diagnostics, TB skin testing (TST), sputum smear and
culture and radiology have remained the mainstay of TB
diagnostics since 1882. TST has been used to support the
diagnosis of TB in populations where TB infection is low. In
South Africa a positive TST can be used to support the
diagnosis in paediatric TB but is of limited use in adult
diagnosis. TST is however still  a useful tool for epidemiological
studies of the annual risk of infection in children but by
adulthood the majority of South Africans have been exposed
to TB. In industrialised countries the TST identifies a minority
of individuals who are at increased risk of disease progression,
to whom diagnostic and preventive resources can be targeted.
In contrast, in South Africa the majority of adults have already
been exposed to TB and in those with advanced HIV infection,
who are at highest risk of disease progression, the test has low
sensitivity with up to 50% false negatives. 
Sputum smear microscopy has high specificity in high TB
prevalence settings. Sputum microscopy has been the
mainstay of TB control programmes as it is able to identify the
most infectious cases. The test is relatively inexpensive and
widely available. Despite its wide availability in the field it is
dependent on highly motivated technicians. The overall
sensitivity for identifying TB infection is 35 - 70%, but the
sensitivity in HIV-infected cases can be as low as 20%.
HIV-positive HIV-negative
adults adults
Prevalence of treated 1 563 352
smear-positive PTB (1 108 - 2 138) (233 - 507)
Prevalence of treated 4 400 527
and untreated smear- (3 619 - 5 299) (280 - 711)
positive PTB
Case finding 0.37 0.67
proportion (0.25 - 0.53) (0.41 - 1.0)
PTB = pulmonary tuberculosis.
TABLE II. PREVALENCE OF TREATED AND UNTREATED
SMEAR-POSITIVE PULMONARY TB WITH ACTIVE CASE
FINDING AMONG HIV-SEROPOSITIVE AND HIV-
SERONEGATIVE INDIVIDUALS
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Diagnosis of TB with a chest X-ray is fast, convenient and has
high sensitivity in HIV-negative individuals. In HIV infection
the radiological findings of active TB disease decrease with the
level of immune suppression, resulting in low sensitivity in
advanced disease.10 The occurrence of opportunistic diseases
that can also mimic the radiological changes of TB results in
lowered specificity in AIDS cases. The combination of relative
expense, restricted availability and low sensitivity and
specificity in HIV infection limits the role of radiology for TB
control in the high HIV prevalence setting.
Mtb culture is sensitive and specific for pulmonary TB in both
HIV-positive and HIV-negative individuals. Solid media culture,
however, is limited by the prolonged time required for positive
and negative results, which can be delayed for 6 - 8 weeks.
Culture of sputum has low sensitivity for extrapulmonary TB,
which occurs more commonly in HIV-infection. TB culture also
requires a high level of laboratory bio-safety, which
consequently restricts its availability to sophisticated
centralised reference laboratories.  
NEW TECHNOLOGIES
Serological diagnosis of TB is a relatively simple and 
inexpensive technology which could be a potentially attractive
strategy for paediatric and adult extrapulmonary TB diagnosis.
A large number of commercially marketed antibody detection
tests are available. In 2005 the WHO performed an evaluation
of available TB rapid diagnostic antibody tests. Nineteen of 27
invited manufacturers agreed to submit their products for
evaluation against a panel of known specimens. The
evaluation study found that the performance of antibody tests
varied widely with high ‘lot to lot’ and ‘reader to reader’
variability. The specificity was less than 80% in the majority of
products. Those tests with higher sensitivity lacked specificity
and detected fewer than 40% of TB cases. The conclusion of
the study was that none of the antibody assays performed
well enough to replace microscopy.11
Liporabinomannan (LAM) is a component of Mtb cell walls,
which is excreted unchanged in urine. A quantitative enzyme-
linked immunoassay (ELISA) has been used to demonstrate a
correlation between urinary LAM concentrations and the level
of Mtb organism load in the sputum of pulmonary TB cases.12
Urinary LAM concentrations may therefore be a reflection of
infecting Mtb organism load, able to diagnose TB in both HIV-
positive and HIV-negative individuals. The quantitative
thresholds of urinary LAM for diagnosis and sensitivity, and
specificity for identifying pulmonary and extra-pulmonary TB,
are still to be defined. The LAM ELISA format is suited for
peripheral laboratory use; however, a simpler ‘tube format’ test
has also been shown to be robust and does not require a cold
chain. A dipstick format of the test is under development,
which could possibly prove be the first TB diagnostic suitable
for use in ‘point of care’ clinics.
Cytokine detection assays are based on the observation that
lymphocytes with immunological memory produce interferon-
gamma (INF-) when re-exposed to a specific antigenic
challenge. Two commercially available assays have been
developed; the QuantiFERON®-TB GOLD, which uses whole
blood as its substrate, and the T-SPOT TB assay, which uses
isolated peripheral blood mononuclear cells. Both assays use
Mtb specific antigens and therefore should not be subject to
cross-reactions due to exposure to other environmental
mycobacteria or exposure to the M. bovis strain used for BCG
vaccination. The performance criteria of these tests for
identifying latently infected individuals in published studies is
in the range of 0.75 - 0.95 for sensitivity and 0.9 - 1.0 for
specificity; however, the sensitivity in HIV-infected individuals
may be reduced.13 The advantage of INF- assays over TST, of
a single visit with a result not subject to observer error, is
offset by the requirement of venepuncture, the cost and the
need for laboratory infrastructure. Although cytokine assays
appear to be more sophisticated and sensitive versions of the
TST, these tests may be measuring differing aspects of the
immune responses to Mtb infection. INF- secretion by cells
incubated with mycobacterial antigens over a week may
reflect long-term immunological memory, while the shorter 3-
day incubation may reflect more recent immunological
memory. We have shown that the 3-day INF- secretion from
PBMCs co-incubated with Mtb antigens is similar in both HIV-
negative and HIV-positive controls, but the secretion from
cells of those with a history of recent TB treatment was
significantly lower than controls (S D Lawn – personal
communication).
CULTURE TECHNIQUES
Culture of Mtb remains the gold standard for both diagnosis 
and drug sensitivity testing. The characteristics of culture and
media and growth detection are shown in Fig. 1. Culture in
liquid media is faster, with results available as soon as 7 days
compared with 42 - 56 days’ required growth on solid media.
A variety of growth detection methodologies have been
utilised. Early detection of growth may be based on
mycobacterial metabolism, identification of microscopic
Culture
• More sensitive than direct sputum smear, requires between 5
and 100 organisms/ml v. 5 000 - 10 000 for positive smear
• Allows species identification and concomitant drug sensitivity
testing (DST)
Media
• Solid media requires 6 - 8 weeks for confirmed diagnosis and
further 4 - 6 weeks for DST
• Liquid culture is faster with results of diagnosis and DST as
soon as 7 days
Growth detection methods
• Radioactivity – BACTEC 460-TB®
• Fluorescence – BACTEC MGIT 960®
• Phage-based tests – FASTPlaque TB-RIF™
• Inverted microscopy – MODS
Fig. 1. Characteristics of Mycobacterium tuberculosis culture.
colonies or macroscopic plaques on secondary organisms. The
BACTEC 460-TB® commercial assay incorporates a radioactive
marker in the liquid media which is detected when growth
occurs. A more recent development, the BACTEC MGIT 960®
assay, utilises a plastic tube containing a broth with a
fluorescence quenching-based oxygen sensor. Consumption
of oxygen by growth of Mtb produces fluorescence when
illuminated by a UV lamp. The non-commercial microscopic
optical detection system (MODS) uses an inverted microscope
to detect characteristic tangles of developing Mtb colonies in
96 well pates. The FAST-plaque™ assay identifies viable
organisms which have been infected with bacteriophages by
the development of macroscopically visible plaques on a lawn
of fast-growing M. smegmatis.14
Drug sensitivity testing (DST) conventionally takes 4 - 6 weeks
after confirmation of primary detection on solid media, a
process which takes 6 - 8 weeks. Liquid culture media can
incorporate antibiotics at the time of initial inoculation, with
the inference that surviving organisms are phenotypically
resistant to the specifically incorporated antibiotic. DST results
can therefore be available within the same time frame as
mycobacterial diagnosis.
NUCLEIC ACID AMPLIFICATION TESTS
Nucleic acid amplification (NAA) is a rapidly evolving
improvement in the detection and identification of Mtb which
requires strong laboratory capacity and good quality control
procedures and is relatively expensive. Bacterial or ribosomal
RNA transcribed into DNA is amplified, followed by an
appropriate reading system using a signal generating probe.
The inclusion of internal positive controls reduces the
incidence of false negatives, and use of a single tube format
can reduce potential for contamination. NAA tests can be used
for TB diagnosis but cannot be used for evaluation of patients
receiving therapy as the technology cannot distinguish
between live and dead organisms. The outstanding feature of
NAA tests is that a positive result together with a high degree
of specificity can be achieved within hours.
NAA tests usually have high specificity but variable sensitivity,
so a positive test is good evidence of infection but a negative
test is less informative. It is considered that current NAA tests
cannot replace microscopy or culture, are unsuitable for
smear-negative disease, and should be used only in
conjunction with these tests and clinical data.15,16 Drug
resistance can be identified by identifying sequences in the
rpoB and katG genes which encode for rifampicin and
isoniazid resistance or by hybridisation of this region with
specific DNA probes. Recent advances in NAA technology
include the ability to amplify directly from clinical samples,
isothermal amplification of DNA and improved amplification
product detection.
The AMPLICOR® MTB test can give a result within 6 - 7 hours
and is a US Federal Drug Administration (FDA) approved test
for confirming smear-positive pulmonary TB. LAMP (loop
mediated isothermal amplification) is able to amplify TB DNA
directly from clinical samples and does not require a
thermocycling device, and a positive result, confirmed by a
colour reaction visible with the naked eye, can be achieved
within 2 hours. With further development a version of the
LAMP test may be suitable for use in peripheral laboratories. A
commercial assay (Hain Lifesciences) allows a specific Mtb
diagnosis together with detection of rifampicin and isoniazid
resistance achieved by PCR amplification of the 16S-23S
ribosomal DNA spacer region followed by hybridisation of the
amplified DNA product with specific oligonucleotide probes.
The probes are immobilised as parallel lines on membrane
strip; however the test format is suited to reference
laboratories rather than lower resourced peripheral
laboratories.
DIAGNOSTIC PIPELINE
There is now more interest and financial investment in the 
development of new TB diagnostics than has occurred over
the prior decades (Fig. 2). The development pipeline is active;
however, most of the immediate advances in diagnosis and
drug sensitivity testing will be applicable only to the reference
laboratory.17 Advances in peripheral laboratory capacity are
2 - 5 years away and are characterised by improved micro-
scopy techniques and development of simplified nucleic acid
amplification methodologies. There is little immediate hope of
improved ‘point of care’ TB diagnostics, where the need is
greatest. The time frame for new tests in the peripheral clinic
is 3 - 7 years and is dependent on formulating simplified
antigen and antibody testing such as dipstick tests. The role of
newer diagnostics with potential to address the spectrum of
clinical scenarios posed by TB and HIV infection are shown in
Table III. 
CONCLUSIONS
The HIV epidemic has reversed the advances made in global 
TB control. The increase in smear-negative disease has
exposed the inadequacies of existing diagnostics which have
remained essentially unchanged since the 1890s. HIV infection
has been associated with decreased sensitivity of all present
diagnostic modalities of TST, sputum microscopy, TB culture
and radiology. Active community case finding indicates that
the present diagnostic algorithm used in the national TB
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Clinical scenario Potentially useful tests
TB infection
HIV negative TST, INF- whole blood assays
HIV positive TST,  INF- isolated PBMC assays
TB disease
Smear-positive Direct smear, rapid Mtb culture, 
phage, NAT
Smear-negative Rapid Mtb culture, urinary LAM
TB treatment failure Rapid Mtb culture with DST 
Drug sensitivity testing Rapid Mtb culture, phage assay, 
NAAT, hybridisation assays
TABLE III. TESTS WITH POTENTIAL TO ADDRESS DIFFERENT
CLINICAL SCENARIOS
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control programme fails to identify a large proportion of HIV-
associated TB. There is therefore an urgent need for point of
care tests with increased sensitivity for screening of HIV-
positive individuals.
The association of HIV-infection with MDR and XDR has also
driven the need for tests which can be used to recognise early
treatment failure and rapid identification of drug resistance.
The rapid progression of TB in HIV-infected individuals
together with increased mortality has also emphasised a need
for much faster identification of infection and failure of
therapy. The development of rapid liquid culture assays and
NAA assays offer significant advances over conventional solid
media culture and drug sensitivity testing.   
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